title: In haematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study.
abstract: The aim of this study was to determine whether parameters related to TBI impacted upon OS and relapse in patients with acute leukemia in CR who underwent haematopoietic SCT (HSCT) in 11 Italian Radiation Oncology Centres. Data were analysed from 507 patients (313 males; 194 females; median age 15 years; 318 with ALL; 188 with AML; 1 case not recorded). Besides 128 autologous transplants, donors included 192 matched siblings, 74 mismatched family members and 113 unrelated individuals. Autologous and allogeneic transplants were analysed separately. Median follow-up was 40.1 months. TBI schedules and HSCT type were closely related. Uni- and multi-variate analyses showed no parameter was significant for OS or relapse in autologous transplantation. Multivariate analysis showed type of transplant and disease impacted significantly on OS in allogeneic transplantation. Disease, GVHD and TBI dose were risk factors for relapse. This analysis illustrates that Italian Transplant Centre use of TBI is in line with international practice. Most Centres adopted a hyperfractionated schedule that is used worldwide (12 Gy in six fractions over 3 days), which appears to have become standard. TBI doses impacted significantly upon relapse rates.
authors.affiliation: Radiation Oncology Section, University of Perugia and Perugia General Hospital, Perugia, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Aristei
authors.forename: A
authors.initials: A
authors.lastname: Santucci
authors.forename: R
authors.initials: R
authors.lastname: Corvò
authors.forename: G
authors.initials: G
authors.lastname: Gardani
authors.forename: U
authors.initials: U
authors.lastname: Ricardi
authors.forename: G
authors.initials: G
authors.lastname: Scarzello
authors.forename: S M
authors.initials: SM
authors.lastname: Magrini
authors.forename: V
authors.initials: V
authors.lastname: Donato
authors.forename: L
authors.initials: L
authors.lastname: Falcinelli
authors.forename: A
authors.initials: A
authors.lastname: Bacigalupo
authors.forename: F
authors.initials: F
authors.lastname: Locatelli
authors.forename: F
authors.initials: F
authors.lastname: Aversa
authors.forename: E
authors.initials: E
authors.lastname: Barbieri
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D064591:Allografts; D064592:Autografts; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000628:therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000628:therapy; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods; D061349:Unrelated Donors